THE ARISING · Longevity & Healthspan
Five-Year Data: Earlier Vutrisiran Linked to Fewer Deaths and Heart Events
Patients with a heart condition who stayed on one drug for five years had roughly 41% to 48% lower risk of death or repeat cardiovascular events than patients who started it later, according to new trial data.
Alnylam presented the five-year results from its HELIOS-B trial at the American Heart Association Scientific Sessions 2026, according to the company announcement. The drug is AMVUTTRA (vutrisiran). It is approved by the FDA for transthyretin amyloid cardiomyopathy, known as ATTR-CM, and for hATTR polyneuropathy. It is given every three months.
The analysis included a two-year open-label extension. It compared patients treated continuously with those who began treatment later. Outcomes were tracked through 60 months.
In the monotherapy group (395 patients), continuous treatment was linked to a 48% lower risk of the combined outcome of all-cause death and recurrent cardiovascular events (hazard ratio 0.515; 95% confidence interval 0.368 to 0.722). Recurrent cardiovascular events alone were 50% lower (rate ratio 0.501).
In the overall population (654 patients), the reductions were 41% for the combined outcome (hazard ratio 0.589) and 41% for recurrent events (rate ratio 0.587).
The company also reported gains in Kansas City Cardiomyopathy Questionnaire scores, a measure of how patients feel and function with heart disease. Two blood markers of heart strain and injury, NT-proBNP and troponin I, stayed stable. Safety through 60 months was consistent with prior experience, according to the company.
A two-year, single-center post hoc exercise analysis of 48 patients showed preserved peak oxygen uptake, with a difference of 1.57 mL/kg/min versus placebo (95% confidence interval 0.14 to 3.00; p=0.031). Peak oxygen uptake reflects how much oxygen the body can use during hard exercise.
The company states that the reported P values are nominal and were not adjusted for multiple comparisons.
These are company-reported figures from an extension in which patients were compared by when they started treatment, not a new randomized comparison.
For readers following ATTR-CM, the relevance is timing: patients treated continuously fared better through 60 months than those who began treatment later.
Next to watch is the full presentation and any peer-reviewed publication of the HELIOS-B five-year analyses.